ABUS Arbutus Biopharma Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: ABUS

Price (delayed)

$3.895

Market cap

$735.05M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.44

Enterprise value

$693.64M

Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple ...

Highlights
The debt has declined by 21% year-on-year and by 4.8% since the previous quarter
ABUS's quick ratio is up by 14% QoQ and by 9% YoY
Arbutus Biopharma's equity has decreased by 20% YoY but it has increased by 8% QoQ
Arbutus Biopharma's revenue has shrunk by 61% YoY and by 28% QoQ
Arbutus Biopharma's gross profit has shrunk by 61% YoY and by 28% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://arbutusbio.com
Peers: NWBO

Key stats

What are the main financial stats of ABUS
Market
Shares outstanding
188.72M
Market cap
$735.05M
Enterprise value
$693.64M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.1
Price to sales (P/S)
52.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
53.41
Earnings
Revenue
$12.99M
EBIT
-$74.08M
EBITDA
-$72.66M
Free cash flow
-$78.9M
Per share
EPS
-$0.44
Free cash flow per share
-$0.45
Book value per share
$0.64
Revenue per share
$0.07
TBVPS
$0.86
Balance sheet
Total assets
$150.29M
Total liabilities
$35.65M
Debt
$1.68M
Equity
$114.64M
Working capital
$115.58M
Liquidity
Debt to equity
0.01
Current ratio
6.69
Quick ratio
6.47
Net debt/EBITDA
0.57
Margins
EBITDA margin
-559.5%
Gross margin
100%
Net margin
-572.8%
Operating margin
-616.6%
Efficiency
Return on assets
-47.2%
Return on equity
-62.7%
Return on invested capital
-68.3%
Return on capital employed
-57%
Return on sales
-570.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABUS stock price

How has the Arbutus Biopharma stock price performed over time
Intraday
-0.64%
1 week
5.56%
1 month
29.4%
1 year
81.16%
YTD
55.8%
QTD
26.05%

Financial performance

How have Arbutus Biopharma's revenue and profit performed over time
Revenue
$12.99M
Gross profit
$12.99M
Operating income
-$80.08M
Net income
-$74.39M
Gross margin
100%
Net margin
-572.8%
ABUS's operating margin has dropped by 193% year-on-year and by 43% since the previous quarter
The net margin has dropped by 171% year-on-year and by 43% since the previous quarter
Arbutus Biopharma's revenue has shrunk by 61% YoY and by 28% QoQ
Arbutus Biopharma's gross profit has shrunk by 61% YoY and by 28% QoQ

Growth

What is Arbutus Biopharma's growth rate over time

Valuation

What is Arbutus Biopharma stock price valuation
P/E
N/A
P/B
6.1
P/S
52.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
53.41
The company's EPS rose by 4.3% YoY
ABUS's price to book (P/B) is 127% higher than its 5-year quarterly average of 2.7 and 81% higher than its last 4 quarters average of 3.4
Arbutus Biopharma's equity has decreased by 20% YoY but it has increased by 8% QoQ
The price to sales (P/S) is 138% higher than the last 4 quarters average of 22.3 and 120% higher than the 5-year quarterly average of 24.1
Arbutus Biopharma's revenue has shrunk by 61% YoY and by 28% QoQ

Efficiency

How efficient is Arbutus Biopharma business performance
The company's return on sales has shrunk by 175% YoY and by 43% QoQ
The ROIC has declined by 39% year-on-year and by 12% since the previous quarter
Arbutus Biopharma's return on assets has decreased by 36% YoY and by 9% QoQ
The ROE is down by 30% year-on-year and by 8% since the previous quarter

Dividends

What is ABUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABUS.

Financial health

How did Arbutus Biopharma financials performed over time
ABUS's total liabilities is down by 25% year-on-year and by 7% since the previous quarter
The company's total assets fell by 21% YoY but it rose by 4.1% QoQ
The debt is 99% smaller than the equity
ABUS's debt to equity has dropped by 50% since the previous quarter
The debt has declined by 21% year-on-year and by 4.8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.